GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (NYSE:EW) » Definitions » Piotroski F-Score

Edwards Lifesciences (Edwards Lifesciences) Piotroski F-Score

: 6 (As of Today)
View and export this data going back to 2000. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Edwards Lifesciences has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Edwards Lifesciences's Piotroski F-Score or its related term are showing as below:

EW' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Edwards Lifesciences was 8. The lowest was 5. And the median was 6.


Edwards Lifesciences Piotroski F-Score Historical Data

The historical data trend for Edwards Lifesciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edwards Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 8.00 5.00 6.00

Edwards Lifesciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 5.00 5.00 6.00

Competitive Comparison

For the Medical Devices subindustry, Edwards Lifesciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences Piotroski F-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 340.5 + 307.1 + 384.9 + 369.9 = $1,402 Mil.
Cash Flow from Operations was 314.1 + 33.6 + 411.5 + 136.6 = $896 Mil.
Revenue was 1459.6 + 1530.2 + 1480.9 + 1534.1 = $6,005 Mil.
Gross Profit was 1130.1 + 1187.2 + 1130.5 + 1177.2 = $4,625 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(8292.5 + 8651.2 + 9004 + 9370.8 + 9363.2) / 5 = $8936.34 Mil.
Total Assets at the begining of this year (Dec22) was $8,293 Mil.
Long-Term Debt & Capital Lease Obligation was $670 Mil.
Total Current Assets was $4,036 Mil.
Total Current Liabilities was $1,195 Mil.
Net Income was 373.6 + 406.4 + 343.5 + 398.4 = $1,522 Mil.

Revenue was 1341.2 + 1373.9 + 1319 + 1348.3 = $5,382 Mil.
Gross Profit was 1041.9 + 1104.5 + 1065.2 + 1090.4 = $4,302 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(8502.6 + 8419.9 + 8425.1 + 8638.2 + 8292.5) / 5 = $8455.66 Mil.
Total Assets at the begining of last year (Dec21) was $8,503 Mil.
Long-Term Debt & Capital Lease Obligation was $666 Mil.
Total Current Assets was $3,096 Mil.
Total Current Liabilities was $1,022 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Edwards Lifesciences's current Net Income (TTM) was 1,402. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Edwards Lifesciences's current Cash Flow from Operations (TTM) was 896. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=1402.4/8292.5
=0.16911667

ROA (Last Year)=Net Income/Total Assets (Dec21)
=1521.9/8502.6
=0.17899231

Edwards Lifesciences's return on assets of this year was 0.16911667. Edwards Lifesciences's return on assets of last year was 0.17899231. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Edwards Lifesciences's current Net Income (TTM) was 1,402. Edwards Lifesciences's current Cash Flow from Operations (TTM) was 896. ==> 896 <= 1,402 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=670/8936.34
=0.07497477

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=665.8/8455.66
=0.07874016

Edwards Lifesciences's gearing of this year was 0.07497477. Edwards Lifesciences's gearing of last year was 0.07874016. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=4035.7/1195.4
=3.37602476

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=3095.8/1022.4
=3.0279734

Edwards Lifesciences's current ratio of this year was 3.37602476. Edwards Lifesciences's current ratio of last year was 3.0279734. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Edwards Lifesciences's number of shares in issue this year was 607. Edwards Lifesciences's number of shares in issue last year was 616.1. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4625/6004.8
=0.77021716

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4302/5382.4
=0.7992717

Edwards Lifesciences's gross margin of this year was 0.77021716. Edwards Lifesciences's gross margin of last year was 0.7992717. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=6004.8/8292.5
=0.72412421

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=5382.4/8502.6
=0.6330299

Edwards Lifesciences's asset turnover of this year was 0.72412421. Edwards Lifesciences's asset turnover of last year was 0.6330299. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+1+1+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Edwards Lifesciences has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Edwards Lifesciences  (NYSE:EW) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Edwards Lifesciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Edwards Lifesciences (Edwards Lifesciences) Business Description

Address
One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
Executives
Bobo Donald E Jr officer: CVP,Strategy/Corp Development C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Michael A Mussallem director, officer: Chairman & CEO C/O EDWARDS LIFESCIENCES CORP, ONE EDWARDS WAY, IRVINE CA 92614
Scott B. Ullem officer: CVP, CFO C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Daveen Chopra officer: CVP, Surgical Structural Heart C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92618
Larry L Wood officer: CVP, THV Replacement C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Catherine M. Szyman officer: CVP, Critical Care C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Wayne Markowitz officer: GM & SVP, Surgical ONE EDWARDS WAY, IRVINE CA 92614
Heisz Leslie Stone director C/O PUBLIC STORAGE, 701 WESTERN AVENUE, GLENDALE CA 91201
Jean-luc M Lemercier officer: CVP, EMEA, Canada, Latin Amer C/O ONE EDWARDS WAY, IRVINE CA 92614
Sellers Robert W.a. officer: VP, Corp. Controller (Principa ONE EDWARDS WAY, IRVINE CA 92614
Bernard J Zovighian officer: CVP, Surgical Heart Valves C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Huimin Wang officer: CVP, Japan & Intercontinental C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Martha H. Marsh director 9769 WEXFORD CIRCLE, GRANITE BAY CA 95746
Kieran Gallahue director PO BOX 684369, PARK CITY UT 84068
Nicholas J Valeriani director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614